Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct;35(10):1215-22.

Uterine sarcoma. Clinico-pathological characteristics and outcome

Hesham K Sait  1 , Nisreen M Anfinan, Mohamed E El Sayed, Shadi S Alkhayyat, Ahmed T Ghanem, Reem M Abayazid, Khalid H Sait
Affiliations

Uterine sarcoma. Clinico-pathological characteristics and outcome

Hesham K Sait et al. Saudi Med J. 2014 Oct.

Abstract

Objectives: To investigate the clinical and histopathological characteristics, with the prognostic factors, treatment outcome, pattern of relapse, and survival analysis of uterine sarcoma patients.

Methods: All patients with histologically proven uterine sarcoma were identified using the database at King Abdulaziz University Hospital, Jeddah, Saudi Arabia between January 2000 and December 2012.

Results: A total of 36 patients with uterine sarcoma were reviewed. The median age of all patients was 57 years, and the mean age was 57.72+/-13.17 years. Carcinosarcoma was reported in 21 patients (58%), leiomyosarcoma in 7 (19%), undifferentiated endometrial sarcoma in 6 (17%), and rhabdomyosarcoma in 2 (6%). Approximately half of the patients were stages III and IV (28% and 25%), while 15 patients (41%) were stage I; only 2 patients (6%) were stage II. The surgical treatment was hysterectomy and bilateral salpingoophorectomy (H+BSO) plus staging in 18 patients (50%), while in 4 patients (19%), H+BSO plus debulking was performed. Adjuvant chemotherapy was given in 24 (69%) and adjuvant radiotherapy in 5 (14%) cases, At a median follow-up period of 13.5 months, 8 patients (22%) relapsed. The 2-year disease-free survival (DFS) rate was 22% and the 5-year was 14%. In the multivariate analysis, the advanced stages (p=0.015) and lymph vascular invasion (p=0.0001) were associated with poor DFS, while the use of chemotherapy significantly improved the DFS (p=0.027).

Conclusions: The poor outcome of high-grade uterine sarcoma patients was identified, and only one third of patients (30%) survived for 2 years. This finding necessitates the need for more aggressive tools to fight this disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Disease-free survival for patients with uterine sarcomas.
Figure 2
Figure 2
Overall survival for patients with uterine sarcomas.
Figure 3
Figure 3
Overall survival for patients with uterine sarcomas per surgical procedure. Log rank, p=0.786.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chauveinc L, Deniaud E, Plancher C, Saastre X, Amesani F, de La Rochefordiere A, et al. Uterine sarcomas: the Curie institute experiences. Prognosis factors and adjuvant treatment. Gynecol Oncl. 1999;72:232–237. - PubMed
    1. Tropé CG, Abeler VM, Kristensen GB. Diagnosis and treatment of sarcoma of the uterus. A review. Acta Oncol. 2012;51:694–695. - PubMed
    1. Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance epidemiology and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol. 2004;93:204–208. - PubMed
    1. Shi Y, Liu Z, Peng Z, Liu H, Yang K, Yao X. The diagnosis and treatment of Mullerian adenosarcoma of the uterus. Aust N Z J Obstet Gynaecol. 2008;48:596–600. - PubMed
    1. Dinh TA, Oliva EA, Fuller AF, Jr, Lee H, Goodman A. The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital. Gynecol Oncol. 2004;92:648–652. - PubMed

MeSH terms

LinkOut - more resources